Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupropion/mecamylamine - Cary Pharmaceuticals

Next Previous
Search
Drug Profile

Bupropion/mecamylamine - Cary Pharmaceuticals

Alternative Names: INT-0003; INT-0003-2005; INT-0003/2005; INT-003-05; QuitPak; Smoking cessation therapy - Cary Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cary Pharmaceuticals
  • Class Norbornanes; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Smoking withdrawal

Highest Development Phases

  • No development reported Smoking withdrawal

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Smoking-withdrawal in USA (PO, Tablet)
  • 28 Feb 2014 Cary Pharmaceuticals seeking partner for phase III and commercial development of bupropion/mecamylamine for Smoking withdrawal. www.carypharma.com
  • 28 Feb 2014 Cary Pharmaceuticals completes a phase I safety and tolerability trial in Smoking withdrawal in USA before February 2014

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top